This was originally published at Global Health TV on Aug. 24, 2015.
There has been a welcome spate of good news coming out of
West Africa in recent weeks on the apparent demise of Ebola, which has caused
the region nothing but misery, illness (27,952 reported cases) and death (11,284
reported deaths) for over a year.
Ebola cases continue to fall. For the week ending Aug. 16, no new cases were reported in Liberia and Sierra Leone, for the first time, has gone one full week without any new cases. Guinea was the only country to report any new cases — but just three.
And The Lancet published “interim results” from research on the efficacy of an Ebola vaccine in Guinea showing a vaccine efficacy of 100%.
The news is undeniably good. In the last week, I read these headlines:
Associated Press: “UN official: Ebola epidemic could be defeated by end of 2015.”
Ebola cases continue to fall. For the week ending Aug. 16, no new cases were reported in Liberia and Sierra Leone, for the first time, has gone one full week without any new cases. Guinea was the only country to report any new cases — but just three.
And The Lancet published “interim results” from research on the efficacy of an Ebola vaccine in Guinea showing a vaccine efficacy of 100%.
The news is undeniably good. In the last week, I read these headlines:
Associated Press: “UN official: Ebola epidemic could be defeated by end of 2015.”
Scientific
American: “Does This Ebola Vaccine Herald the End of the Virus?”
National Public Radio: “Zero Ebola Cases Reported in Sierra Leone as Epidemic Peters Out”
This is all welcome news but if you go beyond the headlines you quickly realize that this epidemic is not yet over.
National Public Radio: “Zero Ebola Cases Reported in Sierra Leone as Epidemic Peters Out”
This is all welcome news but if you go beyond the headlines you quickly realize that this epidemic is not yet over.
The World Health Organization, in its most recent Ebola
situation report of Aug. 19, cautions against premature declarations of
victory in the very first paragraph:
“However, there is still a
significant risk of further transmission. In addition to the large number of
contacts who remain under observation in Guinea and Sierra Leone, 45 contacts
have been lost to follow-up in the Guinean capital Conakry over the past 6
weeks. Several high-risk contacts have also been lost to follow-up in the
Sierra Leonean capital, Freetown. Rapid-response teams remain alert and ready
to respond to further cases.”
Until all of these contacts pass the 21-day follow-up
period, there is every reason to suspect more Ebola cases. And the vanished
contacts in Conakry and Freetown are cause for concern.
Virologist Ian Mackay of the Australian Infectious Diseases
Research Centre writes in this
blog that this good news is subject to caveats.
“Those blissful
stretches [of zero cases] may be punctuated by a case arising from parts
unknown. They may be tracked to a sexual transmission event, or their origins
may never be fully understood … So we’re not at all free and clear of this virus
yet. It’s still a long haul with many weeks of anxious waiting and heightened
vigilance as well as the need to retain the capacity to cope with new cases.
But, that said, we do seem to have taken one more step back from the precipice
we once started into as we imagined an Africa fending off a rolling Ebola
epidemic.”
And as for the exciting news of the Ebola vaccine with 100%
efficacy, this
article on WIRED explains why that number means less than you think. One of
the problems is that the findings are based on incomplete data, according to
WIRED. Another challenge is that since the vaccine was tested while the
epidemic was receding, it is difficult to know if the vaccinated people who
didn’t develop Ebola in the trial were protected by the vaccine or simply
benefited from the decline of the epidemic.
Clearly, this is a breakthrough (for there is nothing else
available against Ebola) and very encouraging. But, just as clearly, more data
is needed to know how efficacious this vaccine really is. And then there’s the
significant challenge of getting the vaccine to those who need it once we know
that it works.
The other major challenge is to restore, and then
strengthen, the health systems of Guinea, Liberia and Sierra Leone, which were weak
even before the epidemic. It will be hard to do that without well-trained and
well-motivated health workers. Their ranks were decimated by Ebola: A
little-reported fact of the epidemic is that the three countries reported 880
confirmed health worker infections since the start of the outbreak, with 512
deaths, according to the WHO.
Craig Spencer, a doctor from New York who was one of four people
stricken with Ebola in the U.S., addressed this challenge in The
New York Times last week:
“If the epidemic’s immediate
impact on the West African health system sounds dire, the probable consequences
are even more unsettling. Immunization levels have dropped across all three
countries, so that, for instance, a regional measles outbreak could cause
hundreds of thousands of cases — and potentially more deaths than Ebola. A
recent World Bank report estimated that maternal mortality could skyrocket,
setting the entire region back with rates not seen in almost two decades.”
Just restoring the health systems to what they were before
Ebola will be a huge challenge. Improving them beyond that status quo, so they
are better able to deal successfully with epidemics of the future will be even
more daunting. But it must be done. The governments of the three countries must
lead the way, with significant help from the international community.
No comments:
Post a Comment